Key result
Carillon device linked to early FMR improvement, with baseline tenting area correlating with EF changes.
Why the study?
Functional mitral regurgitation exacerbates left ventricular dilatation and contributes to remodeling and heart failure, but the effects of percutaneous mitral annuloplasty on reverse remodeling and predictive echo parameters are unclear.
Does percutaneous trans-coronary venous mitral annuloplasty with the Carillon device improve echocardiographic parameters and induce reverse remodeling in patients with functional mitral regurgitation and impaired ejection fraction?
Observational (n=22)
Does percutaneous trans-coronary venous mitral annuloplasty with the Carillon device improve echocardiographic parameters and induce reverse remodeling in patients with functional mitral regurgitation and impaired ejection fraction?
Percutaneous mitral annuloplasty with the Carillon device improves functional mitral regurgitation and induces left ventricular reverse remodeling at 1 month, with baseline mitral tenting area predicting the benefit.
May support short-term Carillon use in selected FMR; hypothesis-generating and requires RCTs before practice change.
OBJECTIVES: The purpose of our study is to verify, whether percutaneous mitral annuloplasty results in reverse remodeling in patients with functional mitral regurgitation (FMR) and impaired ejection fraction (EF) and to investigate which echo parameters may help in prediction of the efficacy of the procedure. BACKGROUND: FMR exacerbates left ventricular (LV) dilatation and contributes to both LV remodeling and heart failure. METHODS: We analyzed baseline and 1 month follow-up data in 22 consecutive patients with FMR, who underwent successful percutaneous trans-coronary venous mitral annuloplasty with the Carillon device. RESULTS: Significant reduction of FMR echo parameters, including vena contracta (VC), effective regurgitant orifice area (EROA), and regurgitant volume (RV) were observed and maintained throughout 1 month follow up and did not correlate with baseline annular, LV or with the left atrial diameters. Baseline mitral tenting area correlated negatively with the relative improvement (% difference) of EROA (r = -0.5898) and RV (r = -0.4363), but not with VC (r = 0.1341). In addition, increased EF as well as a significant reduction in left ventricular diameters were noted. The increase in EF negatively correlated with the change in EROA (r = -0.50058), PISA (r = -0.5327), and RV (r = -0.5457). Baseline mitral tenting area significantly correlated with the 1 month change in EF (r = 0.5946) and stroke volume (r = 0.6913). CONCLUSIONS: The improvement of FMR after treatment with the Carillon device is associated with LV reverse remodeling and an increase in systolic performance, that correlates with the reduction in mitral regurgitation, being not dependent on baseline heart diameters. Mitral tenting area seems to be an important parameter in prediction of benefit from percutaneous mitral annuloplasty.
No takes yet. Share an insight, caveat, or question.
Kałmucki et al. (2016) conducted an observational in Functional mitral regurgitation and impaired ejection fraction (n=22). Percutaneous trans-coronary venous mitral annuloplasty (Carillon device) was evaluated on Echocardiographic parameters of functional mitral regurgitation and left ventricular reverse remodeling. Percutaneous mitral annuloplasty with the Carillon device improved FMR parameters at 1 month, with baseline mitral tenting area correlating with the change in ejection fraction (r=0.5946).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: